Biden Releases Next 15 Medicare Drugs To Be Negotiated
In a parting shot at the incoming Trump administration, outgoing President Biden’s administration issued the next list of 15 drugs subject to negotiations in Medicare. The list was due by February 1, so the early release is a challenge to the Trump administration not to repeal the negotiation law included in the Inflation Reduction Act (IRA). The prices on the 15 drugs would go into effect on January 1, 2027 after a process in 2025. In 2024, prices for the first 10 drugs were set and take effect on January 1, 2026.
The Centers for Medicare and Medicaid Servies (CMS) says that between November 2023 and October 2024 about 5.3 million people with Medicare Part D coverage used these drugs to treat a variety of conditions, such as cancer, type 2 diabetes, and asthma. The drugs accounted for about $41 billion in total gross covered prescription drug costs under Medicare Part D, or about 14%. If you combine these drugs with the 10 drugs with prices set in the first round, over a third of total gross covered prescription drug costs under Medicare Part D will already have been subject to negotiation. Part B medical drugs will be added to the program for price negotiations for 2028.
In a related note, the administration also proposed to make GLP-1 drugs available for weight loss in Medicare if beneficiaries have only obesity and no other disease state usually found when treating conditions with such drugs. Trump will have to decide whether he keeps the provision, which is extremely costly and could further destabilize the standalone Part D program (but also hurt Medicare Advantage).
The drugs for round 2 are:
- Ozempic; Rybelsus; Wegovy
- Trelegy Ellipta
- Xtandi
- Pomalyst
- Ibrance
- Ofev
- Linzess
- Calquence
- Austedo; Austedo XR
- Breo Ellipta
- Tradjenta
- Xifaxan
- Vraylar
- Janumet; Janumet XR
- Otezla
CMS Fact Sheet: https://www.cms.gov/newsroom/press-releases/hhs-announces-15-additional-drugs-selected-medicare-drug-price-negotiations-continued-effort-lower
Additional articles: https://www.modernhealthcare.com/politics-policy/ozempic-wegovy-medicare-price-negotiations and https://www.healthcaredive.com/news/medicare-drug-price-negotiations-second-round-semaglutide/737662/ and https://insidehealthpolicy.com/daily-news/biden-s-hhs-bids-farewell-list-15-drugs-including-glp-1s-next-negotiations and https://thehill.com/policy/healthcare/5091213-medicare-negotiation-drugs-list/ and https://thehill.com/policy/healthcare/5091255-cms-negotiation-ozempic-list/ and https://thehill.com/homenews/5090719-biden-administration-picks-15-more-drugs-for-medicare-negotiation/
(Some articles may require a subscription.)
#ira #drugpricing #medicare #partd #branddrugmakers #biden #trump
https://www.fiercehealthcare.com/payers/biden-names-cancer-diabetes-drugs-price-negotiation-program
